2023 - Research.com Medicine in Finland Leader Award
His study on Internal medicine is mostly dedicated to connecting different topics, such as Odds ratio. He conducted interdisciplinary study in his works that combined Cancer and Mammography. He performs multidisciplinary study in Mammography and Breast cancer in his work. In his research, he performs multidisciplinary study on Breast cancer and Tamoxifen. He incorporates Tamoxifen and Estrogen in his research. He combines Estrogen and Progesterone receptor in his research. His study deals with a combination of Oncology and Cancer research. Jorma Isola combines Cancer research and Cancer in his research. By researching both Pathology and Immunohistochemistry, Jorma Isola produces research that crosses academic boundaries.
The In situ hybridization portion of his research involves studies in Chromogenic in situ hybridization and CISH. His research on Internal medicine frequently links to adjacent areas such as Estrogen. In his works, he undertakes multidisciplinary study on Estrogen and Breast cancer. He integrates many fields, such as Breast cancer and Cancer research, in his works. He integrates many fields in his works, including Cancer research and Oncology. In his papers, Jorma Isola integrates diverse fields, such as Oncology and Gynecology. Jorma Isola conducts interdisciplinary study in the fields of Gynecology and Internal medicine through his works. His Cancer study frequently draws connections between related disciplines such as Mammary gland. In his study, he carries out multidisciplinary Pathology and Endocrinology research.
Jorma Isola undertakes multidisciplinary investigations into Cancer and Cancer research in his work. He merges Cancer research with Cancer in his study. He combines Internal medicine and Oncology in his research. He integrates Oncology with Internal medicine in his study. In most of his Biochemistry studies, his work intersects topics such as Polymerase. Jorma Isola performs multidisciplinary studies into Polymerase and Enzyme in his work. Enzyme and Biochemistry are two areas of study in which Jorma Isola engages in interdisciplinary work. Jorma Isola regularly links together related areas like Hormone therapy in his Breast cancer studies. His research on Hormone therapy often connects related topics like Breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
Tapio Visakorpi;Eija Hyytinen;Pasi Koivisto;Minna Tanner.
Nature Genetics (1995)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu;Pirkko-Liisa Kellokumpu-Lehtinen;Petri Bono;Tuomo Alanko.
The New England Journal of Medicine (2006)
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.
Olli‐P ‐P Kallioniemi;Anne Kallioniemi;Jim Piper;Jorma Isola.
Genes, Chromosomes and Cancer (1994)
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ari Ristimäki;Anna Sivula;Johan Lundin;Mikael Lundin.
Cancer Research (2002)
Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer
Pasi Koivisto;Juha Kononen;Christian Palmberg;Teuvo Tammela.
Cancer Research (1997)
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M. Tanner;M. Hollmén;T. T. Junttila;A. I. Kapanen.
Annals of Oncology (2005)
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Virpi Launonen;Outi Vierimaa;Maija Ht Kiuru;Jorma Isola.
Proceedings of the National Academy of Sciences of the United States of America (2001)
Genetic Changes in Primary and Recurrent Prostate Cancer by Comparative Genomic Hybridization
Tapio Visakorpi;Anne H. Kallioniemi;Ann-Christine Syvänen;Eija R. Hyytinen.
Cancer Research (1995)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal;Peter Johansson;Karolina Holm;Sofia K. Gruvberger-Saal.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line
Peter Nagy;Elza Friedländer;Minna Tanner;Anita I. Kapanen.
Cancer Research (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: